Tech Company Financing Transactions
Cullgen Funding Round
On 4/11/2019, Cullgen announced $16 million in Series A investment from HighLight Capital, Sequoia Capital and private investors.
Transaction Overview
Company Name
Announced On
4/11/2019
Transaction Type
Venture Equity
Amount
$16,000,000
Round
Series A
Investors
HighLight Capital (Lead Investor)
Sequoia Capital (Lead Investor)
Proceeds Purpose
The financing will support the development of Cullgen's internal pipeline of targeted protein degraders in oncology and other diseases, as well as the company's efforts to discover novel E3 ligands that may be used as part of a targeted protein degrader complex.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
12671 High Bluff Dr. 130
San Diego, CA 92130
USA
San Diego, CA 92130
USA
Phone
Website
Email Address
Overview
Cullgen is a privately held biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective therapeutic approaches. We are developing our proprietary technology platform, uSMITE, based on recent advances in the science of protein degradation.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Financial Officer
Thomas Eastling
President
Ying Luo
Vice President
Michael Plewe
VP - Bus. Development
Kazu Kawauchi
Browse more venture capital transactions:
Prev: 4/10/2019: Strive Health venture capital transaction
Next: 4/11/2019: BentoBox venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs